Novel Topical Treatment for Postherpetic Neuralgia
带状疱疹后神经痛的新型局部治疗
基本信息
- 批准号:6991051
- 负责人:
- 金额:$ 19.69万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-01 至 2008-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The goal of this project is to develop a novel topical drug delivery vehicle to treat postherpetic neuralgia [PHN). PHN is defined as pain in the affected dermatome that persists or appears after the rash of herpes zoster (HZ) has healed. Although many cases of PHN resolve over time, for many patients the pain is chronic, causing a devastating impact on quality of life. Systemic treatments for PHN are associated with undesirable adverse effects, which can be particularly problematic for elderly patients. Topical treatments such as capsaicin cream, acetylsalicylic acid (aspirin), anesthetic creams, and lidocaine patches either require multiple daily applications or are limited in their use due to the potential for elevated systemic absorption of the topical compound.
In previous work, Biomedical Development Corporation (BDC) has developed a novel polymer-based coating composition that is useful for several biomedical applications. The coating is capable of sustained topical drug delivery. The objective of this project is to use these coatings as a treatment for the pain associated with postherpetic neuralgia. The Specific Aims of the grant are as follows: Specific Aim 1: Formulate Coatings for the Treatment of Postherpetic Neuralgia Specific Aim 2: Demonstrate Efficacy of Coatings in a Human Clinical Trial Relevance to Public Health: Herpes zoster (shingles) is one of the most common neurologic diseases in the U.S. Although there have been no systematic attempts to investigate the prevalence of post herpetic neuralgia, estimates have ranged from 500,000 to 1 million in the U.S. The incidence of PHN among those with herpes zoster ranges from 10 to 70 percent and increases with advancing age and the intractability of the pain may also increase with age. The incidence of herpes zoster, and therefore the incidence of PHN, is predicted to increase in the coming decades because of both the aging population and as a consequence of childhood varicella vaccination. The ongoing spontaneous pain and particularly the allodynic component of PHN can be debilitating and can lead to co-morbid conditions such as depression, social isolation, anxiety and sleep disturbance, as well as increased health care utilization.
描述(申请人提供):该项目的目标是开发一种新的局部药物输送载体来治疗带状疱疹后神经痛[PHN]。PHN被定义为在带状疱疹(HZ)皮疹痊愈后持续或出现在受影响皮肤处的疼痛。虽然许多PHN病例会随着时间的推移而消失,但对许多患者来说,疼痛是慢性的,对生活质量造成毁灭性的影响。对PHN的系统治疗与不良反应有关,这对老年患者来说可能特别成问题。局部治疗,如辣椒素乳膏、乙酰水杨酸(阿司匹林)、麻醉剂乳膏和利多卡因贴片,要么需要每天多次使用,要么由于局部化合物的潜在全身吸收增加而受到限制。
在之前的工作中,生物医学开发公司(BDC)开发了一种新型的聚合物基涂层组合物,该组合物可用于多种生物医学应用。该涂层能够持续的局部给药。该项目的目标是使用这些涂层作为治疗与带状疱疹后神经痛相关的疼痛。这笔赠款的具体目的如下:具体目标1:配制治疗带状疱疹后神经痛的涂料特殊目标2:在一项与公共卫生相关的人类临床试验中证明涂料的有效性:带状疱疹(带状疱疹)是美国最常见的神经系统疾病之一。虽然还没有系统的尝试来调查带状疱疹后神经痛的患病率,但在美国估计从50万到100万不等。带状疱疹患者的PHN发病率从10%到70%,并随着年龄的增加而增加,疼痛的顽固性也可能随着年龄的增加而增加。由于人口老龄化和儿童接种水痘疫苗的结果,带状疱疹的发病率以及因此PHN的发病率预计在未来几十年将增加。持续的自发性疼痛,特别是PHN的痛觉异常成分,可能会使人虚弱,并可能导致抑郁、社交孤立、焦虑和睡眠障碍等共病情况,以及增加卫生保健利用率。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Charles J Gauntt其他文献
Charles J Gauntt的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Charles J Gauntt', 18)}}的其他基金
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
- 批准号:
8123164 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
- 批准号:
7928457 - 财政年份:2010
- 资助金额:
$ 19.69万 - 项目类别:
Unique Anti-microbial Rinse to Reduce Oral Inflammation
独特的抗菌冲洗剂可减少口腔炎症
- 批准号:
7671912 - 财政年份:2009
- 资助金额:
$ 19.69万 - 项目类别:
Non-Toxic Gel to Treat Vulvovaginal Candidiasis
用于治疗外阴阴道念珠菌病的无毒凝胶
- 批准号:
7051865 - 财政年份:2006
- 资助金额:
$ 19.69万 - 项目类别:
Novel Rinse to Treat Oral Candidiasis in Cancer Patients
治疗癌症患者口腔念珠菌病的新型漱口水
- 批准号:
6989894 - 财政年份:2005
- 资助金额:
$ 19.69万 - 项目类别:
Novel Skin Barrier to Prevent and Treat Poison Ivy
预防和治疗毒藤的新型皮肤屏障
- 批准号:
6833377 - 财政年份:2004
- 资助金额:
$ 19.69万 - 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIE VIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
- 批准号:
2222604 - 财政年份:1991
- 资助金额:
$ 19.69万 - 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIEVIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
- 批准号:
3365094 - 财政年份:1991
- 资助金额:
$ 19.69万 - 项目类别:
CHRONIC MYOCARDITIS IN A COXSACKIEVIRUS MURINE MODEL
柯萨奇病毒鼠模型中的慢性心肌炎
- 批准号:
3365093 - 财政年份:1991
- 资助金额:
$ 19.69万 - 项目类别:
相似国自然基金
O6-methyl-dGTP抑制胶质母细胞瘤的作用及分子机制研究
- 批准号:82304565
- 批准年份:2023
- 资助金额:30.00 万元
- 项目类别:青年科学基金项目
基于Notch-1介导miR-200家族调控上皮间质转化对绒癌耐药机制的研究
- 批准号:81972428
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
地塞米松诱导的人卵巢癌对化疗药物耐受及其机制的研究
- 批准号:81172471
- 批准年份:2011
- 资助金额:57.0 万元
- 项目类别:面上项目
维生素B3促进化疗导致粒细胞减少症的中性粒细胞生成功能及作用机制研究
- 批准号:81060045
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
番荔枝内酯抗肿瘤作用及调节肿瘤耐药分子调控网络研究
- 批准号:30973854
- 批准年份:2009
- 资助金额:20.0 万元
- 项目类别:面上项目
应用蛋白敲除技术降解ErbB家族的抗乳腺癌作用及其机制研究
- 批准号:30901754
- 批准年份:2009
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
卵巢癌肿瘤干细胞特异性microRNA分子靶点调控的研究
- 批准号:30873011
- 批准年份:2008
- 资助金额:34.0 万元
- 项目类别:面上项目
巨噬细胞诱导的大肠癌靶向治疗实验研究
- 批准号:30471998
- 批准年份:2004
- 资助金额:20.0 万元
- 项目类别:面上项目
相似海外基金
The conserved mechanisms underlying different types of chronic pain
不同类型慢性疼痛的保守机制
- 批准号:
10677714 - 财政年份:2022
- 资助金额:
$ 19.69万 - 项目类别:
Inhibition of CaVα-β interaction with orally available small organic molecules for chronic pain
抑制 CaVα-β 与口服小有机分子相互作用治疗慢性疼痛
- 批准号:
10267604 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Optimization of a Gene Therapy for Chronic Pain in Human DRGs
人类 DRG 慢性疼痛基因疗法的优化
- 批准号:
10259387 - 财政年份:2021
- 资助金额:
$ 19.69万 - 项目类别:
Lymphotoxin-beta receptor peripheral signaling regulates the transition to inflammation and neuropathy-induced chronic pain
淋巴毒素-β受体外周信号传导调节向炎症和神经病变引起的慢性疼痛的转变
- 批准号:
10392987 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Lymphotoxin-Beta Receptor Peripheral Signaling Regulates the Transition to Inflammation and Neuropathy-Induced Chronic Pain
淋巴毒素-β 受体外周信号传导调节向炎症和神经病变引起的慢性疼痛的转变
- 批准号:
10601055 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Life after breast cancer treatment: racial health disparities and chronic pain in breast cancer survivors.
乳腺癌治疗后的生活:乳腺癌幸存者的种族健康差异和慢性疼痛。
- 批准号:
9888939 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Developing an intervention to address intersecting prescription opioid and chronic pain stigma in cancer survivors: formative work
制定干预措施以解决癌症幸存者中交叉处方阿片类药物和慢性疼痛耻辱问题:形成性工作
- 批准号:
10173220 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
Lymphotoxin-beta receptor peripheral signaling regulates the transition to inflammation and neuropathy-induced chronic pain
淋巴毒素-β受体外周信号传导调节向炎症和神经病变引起的慢性疼痛的转变
- 批准号:
10164882 - 财政年份:2020
- 资助金额:
$ 19.69万 - 项目类别:
microRNA regulation of NMNAT-mediated Neuroprotection against Peripheral Neuropathy and Chronic Pain
NMNAT 介导的针对周围神经病变和慢性疼痛的神经保护的 microRNA 调节
- 批准号:
10704161 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别:
Optimization of Betulinic Acid analogs for T-type calcium channel inhibition for non-addictive relief of chronic pain
用于 T 型钙通道抑制的桦木酸类似物的优化,用于非成瘾性缓解慢性疼痛
- 批准号:
9907601 - 财政年份:2019
- 资助金额:
$ 19.69万 - 项目类别: